Publications

The TRIMT founders have long-term scientific track records in the fields of coordination chemistry, chelator design, radiopharmaceuticals, radiochemistry and radiotracer production, experimental nuclear medicine, and related areas.

Clinical Publications:

  • M. C. Kreissl, J. Wuestemann, E. Eppard, D. Hescheler, J. Wybranska, D. Kupitz, F. Reissig, F. G. Almaguel, J. Notni*.
    First αvβ6-integrin targeted radioligand therapy of breast cancer using 177Lu-Therahexin.
    Eur. J. Nucl. Med. Mol. Imaging 2026, accepted.
  • H. Karaoğlan*, C. Can, N. Akdeniz, D. Has Şimşek, Y. Güzel, B. Soylu, F. Kepenek, İ. Kaplan, S. Kuyumcu, F. Güzel, D. Denizmen Zorba, F. Kaya İpek, H. Kömek.
    Comparison of the diagnostic accuracy of [68Ga]Ga-Trivehexin PET/computed tomography and [18F]FDG PET/computed tomography in nodal staging of various solid tumors.
    Nucl. Med. Commun. 2026, DOI:10.1097/MNM.0000000000002109
  • J. Wuestemann, E. Eppard, D. Hescheler, J. Wybranska, D. Kupitz, F. Reissig, F. G. Almaguel, A. Al-Ibraheem, J. Notni, M. C. Kreissl*.
    Radioligand therapy of pancreatic ductal adenocarcinoma using an αvβ6-integrin targeting 68Ga/177Lu labeled theranostic pair.
    Eur. J. Nucl. Med. Mol. Imaging 2025, DOI:10.1007/s00259-025-07701-5
  • H. Wu, C. Li, L. Li, Y. Tian, Z. Xiao, Y. Huang, J. Zhong, J. Huang*, Q. Chen, Y. He*.
    Integrin αvβ6-Targeted PET/CT Imaging of Non-Small Cell Lung Cancer with [68Ga]Ga-Trivehexin: Improved Preoperative Lymph Node Staging and Association with Immunohistochemistry.
    Adv. Sci. 2025, 12, 8225-8239. DOI:10.1002/advs.202508225
  • F. Marafi*, T. Alahmad, M. Alfeeli, A. Sadeq.
    Triple Negative Breast Cancer and 68Ga-Trivehexin: A Glance of Hope.
    Clin. Nucl. Med. 2026, 51, 50-51. DOI:10.1097/RLU.0000000000005963
  • S. Kar*, V. Lele, N. Shaikh.
    68Ga-Trivehexin Uptake in Brown Tumors in Hyperparathyroidism: A Novel Finding.
    Clin. Nucl. Med. 2026, 51, 46-47. DOI:10.1097/RLU.0000000000005989
  • Z. Liu, C. Li, Z. Xiao, N. Lu, Y. He*.
    68Ga-Trivehexin PET/CT Enhances Detection of Small Primary Lesions Than 18F-FDG PET/CT in Breast Cancer.
    Clin. Nucl. Med. 2025, DOI:10.1097/RLU.0000000000006031
  • D. Denizmen Zorba*, E. G. Işık, D. F. Arslan, C. Sen, S. Kuyumcu.
    Enhancing Nasopharyngeal Cancer Follow-up: 68Ga-Trivehexin PET/CT for Distinguishing Recurrence From Infection.
    Clin. Nucl. Med. 2025, DOI:10.1097/RLU.0000000000006015
  • K. Dvořáková Bendová, T. Groll, B. Neužilová, K. Krasulová, Z. Nový, F. Reissig, K. Steiger, M. Boxberg, E. Eppard, J. Wuestemann, M. Hajdúch, M. Jesinghaus, J. Šimeček, M. C. Kreissl, M. Petřík, J. Notni*.
    PET/CT imaging of esophageal cancer targeting tumor cell specific αvβ6-integrin expression.
    Eur. J. Nucl. Med. Mol. Imaging 2025, 53, 607-618. DOI:10.1007/s00259-025-07408-7
  • A. Sadeq*, W. Fathallah, A. Baqer, K. Agrawal, G. Gnanasegaran, F. Marafi.
    αvβ6 Imaging With 68Ga-Trivehexin PET/CT in Pituitary Macroadenoma.
    Clin. Nucl. Med. 2025, 50, 717-719. DOI:10.1097/RLU.0000000000005950
  • G. Beydağı, N. A. Selçuk, K. Akçay, O. Yaprak, M. Kalaycı, L. Kabasakal.
    Cancer integrin imaging with [68Ga]Ga-Trivehexin PET/CT for a patient with breast cancer and neuroendocrine neoplasm: A case of both (18F)FDG PET/CT and [68Ga]Ga-DOTATATE positive but integrin αvβ6 negative lesion on [68Ga]Ga-Trivehexin PET.
    Mol. Imaging Radionucl. Ther. 2025, 34, 143-145. DOI:10.4274/mirt.galenos.2024.60320
  • D. Denizmen Zorba*, S. Kuyumcu, A. Kubat Üzüm, E. G. Işık, Y. Şanlı.
    Detection of Recurrent Parathyroid Cancer Using 68Ga-Trivehexin PET/CT.
    Clin. Nucl. Med. 2025, 50, 451-452. DOI:10.1097/RLU.0000000000005735
  • S. Kuyumcu*, D. Denizmen Zorba, Z. G. Özkan.
    68Ga-Trivehexin PET/CT uptake in malignant and fibrotic lung tissue: refining diagnostic applications.
    Eur. J. Nucl. Med. Mol. Imaging 2025, 52, 3513-3514. DOI:10.1007/s00259-025-07193-3
  • H. Wu, L. Li, Z. Xiao, Q. Chen, C. Li, Y. He*.
    [68Ga]Ga-Trivehexin PET/CT imaging of integrin-αvβ6 expression in concomitant mucinous lung adenocarcinoma and idiopathic pulmonary fibrosis.
    Eur. J. Nucl. Med. Mol. Imaging 2025, 52, 3053-3055. DOI:10.1007/s00259-025-07146-w
  • F. Novruzov*, E. Mehdi, N. Aliyeva, P. Orucova, J. Šimeček, J. Aliyev.
    The true negative [68Ga]Ga-Trivehexin PET/CT in Solid Pseudopapillary Neoplasm of pancreas, mimicking pancreatic adenocarcinoma in [18F]FDG and [68Ga]Ga-FAPI scans.
    Eur. J. Nucl. Med. Mol. Imaging 2024, 52, 1942-1943. DOI:10.1007/s00259-024-06972-8
  • R. Emerson, K. Agrawal*, P. Singh, P. S. S. Patro, N. Kumar.
    Cancer Integrin Imaging With 68Ga-Trivehexin PET-CT in Head and Neck Squamous Cell Carcinoma Improves Diagnostic Accuracy.
    Clin. Nucl. Med. 2024, 50, 180-181. DOI:10.1097/RLU.0000000000005582
  • H. Kömek, Y. Güzel*, İ. Kaplan, E. E. Yilmaz, C. Can.
    Superiority of 68Ga-Trivehexin PET/CT Over 18F-FDG PET/CT in the Evaluation of Lymph Nodes in Patients With Breast Cancer.
    Clin. Nucl. Med. 2024, 50, 175-177. DOI:10.1097/RLU.0000000000005585
  • T. Singhal, K. Agrawal*, S. Mandal, G. K. Parida, Girish Kumar.
    Cancer-Specific Integrin Imaging With 68Ga-Trivehexin: A Potential Imaging for Accurate Staging of Thyroid Malignancy.
    Clin. Nucl. Med. 2024, 50, 168-170. DOI:10.1097/RLU.0000000000005557
  • J. Rehm*, R. Winzer, M. Pretze, J. Müller, J. Notni, S. Hempel, M. Distler, G. Folprecht, J. Kotzerke.
    αvβ6-Integrin targeted PET/CT imaging in pancreatic cancer patients using 68Ga-Trivehexin.
    Front. Nucl. Med. 2024, 4, 1487602. DOI:10.3389/fnume.2024.1487602
  • H. Wu, L. Li, Z. Xiao, C. Li, Y. He.
    αvβ6-integrin targeted [68Ga]Ga-Trivehexin PET/CT imaging of a rare bronchial mucoepidermoid carcinoma.
    Eur. J. Nucl. Med. Mol. Imaging 2024, 52, 1291-1292. DOI:10.1007/s00259-024-06974-6
  • P. Singh, K. Agrawal*, R. Emerson, A. Baranwal, P. S. S. Patro, G. K. Parida.
    ’Cancer Integrin’ αvβ6 Imaging With 68Ga-Trivehexin PET/CT in Assessment of Ovarian Carcinoma.
    Clin. Nucl. Med. 2024, 49, 619-621. DOI:10.1097/RLU.0000000000005485
  • F. Marafi*, A. Esmail, M. Alfeeli, A. Sadeq.
    68Ga-Trivehexin PET/CT in Metastatic Non-Small Cell Lung Cancer to the Brain.
    Clin. Nucl. Med. 2024, 49, 971-972. DOI:10.1097/RLU.0000000000005406
  • B. Wang, Y. Jiang, J. Zhu, H. Wu, J. Wu, L. Li, J. Huang, Z. Xiao, Y. He*.
    Fully-automated production of [68Ga]Ga-Trivehexin for clinical application and its biodistribution in healthy volunteers.
    Front. Oncol. 2024, 14, 1445415. DOI:10.3389/fonc.2024.1445415
  • S. Kuyumcu*, D. Denizmen, D. Has-Şimşek, A. Poyanli, A. Kubat Üzüm, F. Büyükkaya, E. G. Işık, S. Önder, N. Aksakal, Z. G. Özkan, Y. Şanlı.
    68Ga-Trivehexin PET/CT: a promising novel tracer for primary hyperparathyroidism.
    Eur. J. Nucl. Med. Mol. Imaging 2024, 51, 3912-3923. DOI:10.1007/s00259-024-06846-z
  • S. S. Das, S. Ahlawat, P. Thakral, Parul, D. Malik*, J. Šimeček, C. B. Virupakshappa, M. Koley, J. Gupta, I. Sen.
    Potential Efficacy of 68Ga-Trivehexin PET/CT and Immunohistochemical Validation of αvβ6 Integrin Expression in Patients With Head and Neck Squamous Cell Carcinoma and Pancreatic Ductal Adenocarcinoma.
    Clin. Nucl. Med. 2024, 49, 733-740. DOI:10.1097/RLU.0000000000005278
  • J. Rehm*, R. Winzer, J. Notni, S. Hempel, M. Distler, G. Folprecht, J. Kotzerke.
    Concomitant metastatic head-and-neck cancer and pancreatic cancer assessed by αvβ6-integrin PET/CT using 68Ga-Trivehexin: Incidental detection of a brain metastasis.
    Eur. J. Nucl. Med. Mol. Imaging 2024, 51, 3469-3471. DOI:10.1007/s00259-024-06750-6
  • P. Thakral, S. S. Das, S. Dhiman, D. Manda, C. B. Virupakshappa, D. Malik, and I. Sen*.
    Validation of In-House Kit-Like Synthesis of 68Ga-Trivehexin and Its Biodistribution for Targeting the Integrin αvβ6 Expressing Tumors.
    Cancer Biother. Radiopharm. 2023, 38, 468-475. DOI:10.1089/cbr.2022.0080
  • N. G. Quigley, K. Steiger, S. Hoberück, N. Czech, M. A. Zierke, S. Kossatz, M. Pretze, F. Richter, W. Weichert, C. Pox, J. Kotzerke, J. Notni*.
    PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the “Cancer Integrin” αvβ6 with Ga-68-Trivehexin.
    Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 1136-1147. DOI:10.1007/s00259-021-05559-x
  • N. G. Quigley, N. Czech, W. Sendt, J. Notni*.
    PET/CT imaging of pancreatic carcinoma targeting the “cancer integrin” αvβ6.
    Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 4107-4108. DOI:10.1007/s00259-021-05443-8

Development/Preclinical Publications:

  • T. Rheinfrank, V. Lebruška, S. Stangl, M. Vojtíčková, N. T. Nguyen, L. Koller, J. Šimeček, V. Kubíček, S. Kossatz*, J. Notni*.
    Three Is A Magic Number: Tailored Clickable Chelators Used to Determine Optimal RGD-Peptide Multiplicity in αvβ6-Integrin Targeted 177Lu–labeled Cancer Theranostics.
    Bioconjugate Chem. 2024, 35, 1970-1984. DOI:10.1021/acs.bioconjchem.4c00481
  • S. Stangl, N. T. Nguyen, J. Brosch-Lenz, J. Šimeček, W. A. Weber, S. Kossatz*, J. Notni*.
    Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: Considerations on clinical safety profiles.
    Eur. J. Nucl. Med. Mol. Imaging 2024, 51, 3191-3201. DOI:10.1007/s00259-024-06738-2
  • N. G. Quigley, M. A. Zierke, B. S. Ludwig, F. Richter, N. T. Nguyen, F. Reissig, J. Šimeček, S. Kossatz, J. Notni*.
    The importance of tyrosines in multimers of cyclic RGD nonapeptides: towards αvβ6-integrin targeted radiotherapeutics.
    RSC Med. Chem. 2024, 15, 2018-2029. DOI:10.1039/D4MD00073K
  • N. G. Quigley, F. Richter, S. Kossatz, J. Notni*.
    Complexity of αvβ6-Integrin Targeting RGD Peptide Trimers: Emergence of Non-Specific Binding by Synergistic Interaction.
    RSC Med. Chem. 2023, 14, 2564-2573. DOI:10.1039/d3md00365e

Reviews/Background Information:

  • L. Urso, R. Napolitano, G. Speltri, M. Tuncel, I. Badran*, L. Uccelli, F. Porto, P. Martini, A. Niorettini, C. Cittanti, M. Bartolomei, A. Bosch.
    68Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and Perspectives.
    Cancers 2025, 17, 1504-1520. DOI:10.3390/cancers17091504
  • R. H. Kimura*, A. Iagaru, H. H. Guo.
    Mini review of first-in-human integrin αvβ6 PET tracers.
    Front. Nucl. Med. 2023, 3, 1271208-1271215. DOI:10.3389/fnume.2023.1271208
  • J. Notni*.
    RGD Forever!—Past, Present, and Future of a 3-Letter-Code in Radiopharmacy and Life Sciences.
    Pharmaceuticals 2023, 16, 56-66. DOI:10.3390/ph16010056
  • K. Steiger, N. G. Quigley, T. Groll, F. Richter, M. A. Zierke, A. J. Beer, W. Weichert, M. Schwaiger, S. Kossatz, J. Notni*.
    There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography.
    EJNMMI Res. 2021, 11, 106-120. DOI:10.1186/s13550-021-00842-2
  • S. Kossatz, A. J. Beer, J. Notni*.
    It’s Time to Shift the Paradigm: Translation and Clinical Application of Non‐αvβ3 Integrin Targeting Radiopharmaceuticals.
    Cancers 2021, 13, 5958-5976. DOI:10.3390/cancers13235958
  • K. Steiger, A. -M. Schlitter, W. Weichert, I. Esposito, H. -J. Wester, J. Notni*.
    Perspective of αvβ6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions.
    Mol. Imaging 2017, 16, 1536012117709384. DOI:10.1177/1536012117709384
  • M. Nieberler*, U. Reuning, F. Reichart, J. Notni, H. -J. Wester, M. Schwaiger, M. Weinmüller, A. Räder, K. Steiger, H. Kessler*.
    Exploring the Role of RGD-Recognizing Integrins in Cancer.
    Cancers 2017, 9, 116-149. DOI:10.3390/cancers9090116
  • S. Procházková, V. Kubíček*, J. Kotek, A. Vágner, J. Notni, P. Hermann.
    Lanthanide(III) complexes of monophosphinate / monophosphonate DOTA-analogues: effects of the substituents on the formation rate and radiolabelling yield.
    Dalton Trans. 2018, 13006-13015. DOI:10.1039/c8dt02608d
  • A. Vágner, A. Forgács, E. Brücher, I. Tóth, A. Maiocchi, A. Wurzer, H.-J. Wester, J. Notni, Z. Baranyai*.
    Equilibrium thermodynamics, formation and dissociation kinetics of trivalent iron and gallium complexes of triazacyclononane-triphosphinate (TRAP) chelators: Unraveling the foundations of highly selective Ga-68 labeling.
    Front. Chem. 2018, 6, 170-182. DOI:10.3389/fchem.2018.00170
  • A. Wurzer, A. Vágner, D. Horváth, F. Fellegi, H.-J. Wester, F. K. Kálmán, J. Notni*.
    Synthesis of symmetrical tetrameric conjugates of the radiolanthanide chelator DOTPI for application in endoradiotherapy by means of click chemistry.
    Front. Chem. 2018, 6, 107-118. DOI:10.3389/fchem.2018.00107
  • J. Notni*, H.-J. Wester.
    A practical guide on synthesis of metal chelates for molecular imaging and therapy by means of click chemistry.
    Chem. Eur. J. 2016, 22, 11500-11508. DOI:10.1002/chem.201600928
  • Z. Baranyai, D. Reich, A. Vágner, M. Weineisen, I. Tóth, H.-J. Wester, J. Notni*.
    A shortcut to high-affinity Ga-68 and Cu-64 radiopharmaceuticals: one-pot click chemistry trimerisation on the TRAP platform.
    Dalton Trans. 2015, 44, 11137-11146. DOI:10.1039/C5DT00576K
  • G. Máté, J. Šimeček, M. Pniok, I. Kertész, J. Notni, H.-J. Wester, L. Galuska, P. Hermann*.
    The Influence of the Combination of Carboxylate and Phosphinate Pendant Arms in 1,4,7-Triazacyclononane-based Chelators on their 68Ga Labelling Properties.
    Molecules 2015, 20, 13112-13126. DOI:10.3390/molecules200713112
  • S. Poty, P. Désogère, J. Šimeček, C. Bernhard, V. Goncalves, C. Goze, F. Boschetti, J. Notni, H.-J. Wester, F. Denat*.
    MA-NOTMP: A Triazacyclononane Trimethylphosphinate Based Bifunctional Chelator for Gallium Radiolabelling of Biomolecules.
    ChemMedChem 2015, 5, 618-630. DOI:10.1002/cmdc.201500198
  • J. Notni*, J. Šimeček, H.-J. Wester.
    Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics: unique characteristics and applications.
    ChemMedChem 2014, 9, 1107-1115. DOI:10.1002/cmdc.201400055
  • J. Šimeček, O. Zemek, P. Hermann, J. Notni*, H.-J. Wester.
    The Tailored Gallium(III) Chelator NOPO: Synthesis, Characterization, Bioconjugation, and Application in Preclinical PET Imaging.
    Mol. Pharm. 2014, 11, 3893-3903. DOI:10.1021/mp400642s
  • J. Šimeček, P. Hermann, J. Havlíčková, E. Herdtweck, T. G. Kapp, N. Engelbogen, H. Kessler, H.-J. Wester, J. Notni*.
    A cyclen-based tetraphosphinate chelator for preparation of radiolabeled tetrameric bioconjugates.
    Chem. Eur. J. 2013, 19, 7748-7757. DOI:10.1002/chem.201300338
  • J. Šimeček, P. Hermann, H.-J. Wester, J. Notni*.
    How is 68Ga-labelling of macrocyclic chelators influenced by metal ion contaminants in 68Ge/68Ga generator eluates?
    ChemMedChem 2013, 8, 95-103. DOI:10.1002/cmdc.201200471
  • J. Šimeček, H.-J. Wester, J. Notni*.
    Copper-64 labelling of triazacyclononane-triphosphinate chelators.
    Dalton Trans. 2012, 41, 13803-13806. DOI:10.1039/c2dt31880f
  • J. Notni*, K. Pohle, H.-J. Wester.
    Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET.
    EJNMMI Res. 2012, 2, 28-33. DOI:10.1186/2191-219X-2-28
  • J. Šimeček, O. Zemek, P. Hermann, H.-J. Wester, J. Notni*.
    A monoreactive bifunctional triazacyclononane-phosphinate chelator with high selectivity for Gallium-68.
    ChemMedChem 2012, 7, 1375-1378. DOI:10.1002/cmdc.201200261
  • J. Šimeček, M. Schulz, J. Notni, J. Plutnar, V. Kubíček, J. Havlíčková, P. Hermann*.
    Complexation of Metal Ions with TRAP (1,4,7-Triazacyclononane-Phosphinic Acid) Ligands and 1,4,7-Triazacyclononane-1,4,7-triacetic Acid: Phosphinate-Containing Ligands as Unique Chelators for Trivalent Gallium.
    Inorg. Chem. 2012, 51, 577-590. DOI:10.1021/ic202103v
  • J. Notni*, J. Šimeček, P. Hermann, H.-J. Wester.
    TRAP, a Powerful and Versatile Framework for Gallium-68 Radiopharmaceuticals.
    Chem. Eur. J. 2011, 17, 14718-14722. DOI:10.1002/chem.201103503
  • J. Notni, P. Hermann*, J. Havlíčková, J. Kotek, V. Kubíček, J. Plutnar, N. Loktionova, P. J. Riss, F. Rösch, I. Lukeš.
    A triazacyclononane-based bifunctional phosphinate ligand for the preparation of multimeric 68Ga tracers for positron emission tomography.
    Chem. Eur. J. 2010, 16, 7174-7185. DOI:10.1002/chem.200903281

PD-L1 – Immune Checkpoint:

  • N. G. Quigley, K. Steiger, S. F. Färber, F. Richter, W. Weichert, J. Notni*.
    Sensitive positron emission tomography imaging of PD-L1 expression in human breast and lung carcinoma xenografts using the radiometalated peptide Ga-68-TRAP-WL12.
    Mol. Pharm. 2024, 21, 1827-1837. DOI:10.1021/acs.molpharmaceut.3c01128

Integrins (αvβ6, αvβ8, α5β1, αvβ3):

  • N. G. Quigley, K. Steiger, F. Richter, W. Weichert, S. Hoberück, J. Kotzerke, J. Notni*.
    Tracking a TGF-β Activator In Vivo: Sensitive PET Imaging of αvβ8-Integrin with the Ga-68 Labeled Cyclic RGD Octapeptide Trimer Ga-68-Triveoctin.
    EJNMMI Res. 2020, 10, 133-145. DOI:10.1186/s13550-020-00706-1
  • N. G. Quigley, S. Tomassi, F. S. Di Leva, S. Di Maro, F. Richter, K. Steiger, S. Kossatz, L. Marinelli, J. Notni*.
    Click-chemistry (CuAAC) Trimerization of an αvβ6-Integrin Targeting Ga-68-Peptide: Enhanced Contrast for In-vivo PET imaging of Human Lung Adenocarcinoma Xenografts.
    ChemBioChem 2020, 21, 2836-2843. DOI:10.1002/cbic.202000200
  • J. Notni*, F. T. Gassert, K. Steiger, P. Sommer, W. Weichert, E. J. Rummeny, M. Schwaiger, H. Kessler, R. Meier, M. A. Kimm.
    In-Vivo Imaging of Early Stages of Rheumatoid Arthritis by α5β1-Integrin Targeted Positron Emission Tomography.
    EJNMMI Res. 2019, 9, 87-96. DOI:10.1186/s13550-019-0541-6
  • F. Reichart, O. V. Maltsev, T. G. Kapp, A. F. B. Räder, M. Weinmüller, U. K. Marelli, J. Notni, A. Wurzer, R. Beck, H.-J. Wester, K. Steiger, S. Di Maro, F. Saverio Di Leva, L. Marinelli, M. Nieberler, U. Reuning, M. Schwaiger, H. Kessler*.
    Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide.
    J. Med. Chem. 2019, 62, 2024-2037. DOI:10.1021/acs.jmedchem.8b01588
  • T. G. Kapp, F. S. Di Leva, J. Notni, A. F. B. Räder, M. Fottner, D. Reich, A. Wurzer, K. Steiger, E. Novellino, U. K. Marelli, H.-J. Wester, L. Marinelli, H. Kessler*.
    N-methylation of isoDGR Peptides: Discovery of a Selective α5β1-Integrin Antagonist as Potent Tumor Imaging Agent.
    J. Med. Chem. 2018, 61, 2490-2099. DOI:10.1021/acs.jmedchem.7b01752
  • S. F. Färber, A. Wurzer, F. Reichart, R. Beck, H. Kessler, H.-J. Wester, J. Notni*.
    Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6.
    ACS Omega 2018, 3, 2428-2436. DOI:10.1021/acsomega.8b00035
  • J. Notni*, D. Reich, O. V. Maltsev, T. G. Kapp, K. Steiger, F. Hoffmann, I. Esposito, W. Weichert, H. Kessler, H.-J. Wester.
    In-vivo PET Imaging of the Cancer Integrin αvβ6 Using 68Ga-Labeled Cyclic RGD Nonapeptides.
    J. Nucl. Med. 2017, 58, 671-677. DOI:10.2967/jnumed.116.182824
  • J. Notni*, K. Steiger, F. Hoffmann, D. Reich, M. Schwaiger, H. Kessler, H.-J. Wester.
    Variation of Specific Activities of Ga-68-Aquibeprin and Ga-68-Avebetrin Enables Selective PET-Imaging of Different Expression Levels of Integrins α5β1 and αvβ3.
    J. Nucl. Med. 2016, 57, 1618-1624. DOI:10.2967/jnumed.116.173948
  • J. Notni*, K. Steiger, F. Hoffmann, D. Reich, T. G. Kapp, F. Rechenmacher, S. Neubauer, H. Kessler, H.-J. Wester.
    Complementary, Selective PET-Imaging of Integrin Subtypes α5β1 and αvβ3 Using Ga-68-Aquibeprin and Ga-68-Avebetrin.
    J. Nucl. Med. 2016, 57, 460-466. DOI:10.2967/jnumed.115.165720
  • C. D’Alessandria*, K. Pohle, F. Rechenmacher, S. Neubauer, J. Notni, H.-J. Wester, M. Schwaiger, H. Kessler, A. J. Beer.
    In vivo biokinetic and metabolic characterization of the 68Ga-labeled α5β1-selective peptidomimetic FR366.
    Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 953-963. DOI:10.1007/s00259-015-3218-z
  • J. Šimeček, J. Notni*, T. G. Kapp, H. Kessler, H.-J. Wester.
    Benefits of NOPO as chelator in Gallium-68 peptides, exemplified by preclinical characterization of 68Ga-NOPO-c(RGDfK).
    Mol. Pharm. 2014, 11, 1687-1695. DOI:10.1021/mp5000746
  • I. Laitinen*, J. Notni, K. Pohle, M. Rudelius, E. Farrell, S. G. Nekolla, G. Henriksen, S. Neubauer, H. Kessler, H.-J. Wester, M. Schwaiger.
    Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction.
    EJNMMI Res. 2013, 3, 38-47. DOI:10.1186/2191-219X-3-38
  • J. Notni*, K. Pohle, H.-J. Wester.
    Be spoilt for choice with radiolabelled RGD peptides: Preclinical evaluation of 68Ga-TRAP(RGD)3.
    Nucl. Med. Biol. 2013, 40, 33-41. DOI:10.1016/j.nucmedbio.2012.08.006
  • K. Pohle*, J. Notni, J. Bussemer, H. Kessler, M. Schwaiger, A. J. Beer.
    68Ga-NODAGA-RGD is a suitable substitute for 18F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process.
    Nucl. Med. Biol. 2012, 39, 777-784. DOI:10.1016/j.nucmedbio.2012.02.006

Other conjugates:

  • J. Notni*, J. Plutnar, H.-J. Wester.
    Bone Seeking TRAP Conjugates: Surprising Observations and Implications on Development of Gallium-68-labeled Bisphosphonates.
    EJNMMI Res. 2012, 2, 13-17. DOI:10.1186/2191-219X-2-13